P53-dependent antiproliferative and antitumor effect of novel alkyl series of diorganotin(IV) compounds
Investigational New Drugs, ISSN: 0167-6997, Vol: 27, Issue: 4, Page: 319-326
2009
- 21Citations
- 12Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations21
- Citation Indexes21
- 21
- CrossRef11
- Captures12
- Readers12
- 12
Article Description
Purpose: A series of diorganotin(IV) dichloride complexes of N-(2-pyridylmethylene)arylamine (nitrogen-chelating ligands) have been synthesized and characterized. The present study was carried out to investigate the comparative anti-proliferative and anti-tumor effect of Me SnClL (OTC-1), EtSnCl L (OTC-2) and BuSnCl.L (OTC-3) in combination with X-rays (1.5 Gy). Method: The cytotoxicity of these diorganotin(IV) compounds was studied in human peripheral lymphocytes and the antitumor activity was assessed in Dalton's lymphoma cells. The involvement of proteins that regulate cell cycle and apoptosis was investigated to elucidate the mechanism of their action. Results: 5 mg kg of OTC-3 showed better antiproliferative and antitumor activity than OTC-1 and OTC-2, both as alone or in combination with X-rays. The maximum enhancement of exchange aberrations and the level of p53 and p16 proteins were observed in the OTC-3 treated samples. Upregulated expression of p53 caused a significant down-regulated transcriptionally repression of Survivin in OTC-3 treated human lymphocytes. Conclusion: It could be possible that after treatment with either OTC-3 alone or in combination with X-rays the Dalton's lymphoma cells may die apoptotically after inducing initial delay in cell cycle and thereby survivality of mouse bearing Dalton's Lymphoma cells was increased significantly. © 2008 Springer Science+Business Media, LLC.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=67651146914&origin=inward; http://dx.doi.org/10.1007/s10637-008-9176-6; http://www.ncbi.nlm.nih.gov/pubmed/18802665; http://link.springer.com/10.1007/s10637-008-9176-6; https://dx.doi.org/10.1007/s10637-008-9176-6; https://link.springer.com/article/10.1007/s10637-008-9176-6; http://www.springerlink.com/index/10.1007/s10637-008-9176-6; http://www.springerlink.com/index/pdf/10.1007/s10637-008-9176-6
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know